Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company's NeXT Personal ® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, Illinois.
'Our collaborators are excited to present new data, including initial results from the VICTORI study where NeXT Personal is being used to identify residual and recurrent colorectal cancer in patients. With a more sensitive test, our goal is to improve patient outcomes by finding and treating colorectal cancer recurrence earlier. We are also thrilled that NeXT Personal results from the TRACERx collaboration, one of the largest ctDNA studies in early-stage lung cancer, will be presented at the meeting,' said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.
The two oral presentations are:
Oral Presentation: Detection of post-surgical minimal residual disease (MRD) in colorectal cancer; preliminary results from the VICTORI study
Time: April 28, 2025, 3:35 PM - 3:50 PM
Location: Room S105 - McCormick Place South (Level 1)
Presenter: Emma Titmuss, BC Cancer, Vancouver, BC, Canada
Oral Presentation: Ultrasensitive MRD detection: Results from TRACERx
Time:
Location: Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)
Presenter: Charles Swanton, The Francis Crick Institute, London, United Kingdom
Additionally, a poster presentation detailing results from clinical NeXT Personal testing across >15 different cancer types will be presented:
Poster Presentation: Impact of an ultrasensitive ctDNA test on MRD detection in real world clinical patient testing
Time: April 29, 2025, 9:00 AM - 12:00 PM
Location: Section 29, poster 4549
Presenter: Rachel Marty Pyke, Personalis, Inc., Fremont, CA
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are 'forward-looking statements' within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor a patient's response to therapy, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.
Not affiliated with or endorsed by AACR.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
AIDS 5K Walk/Run cancelled due to wildfire smoke
LIVERPOOL, N.Y. (WSYR-TV) — The Canadian wildfire smoke in Central New York has caused the AIDS 5K Walk/Run to be cancelled. The run was originally scheduled for Sunday, June 8, 2025 at Onondaga Lake Park in Liverpool at the Saw Mill Creek Shelter. The decision to cancel the event was made because the air quality at this level can affect sensitive groups and others, especially during physical activity. The Air Quality Alert for Central New York will last until Sunday, 11:59 June 8. Organizers will share more information in the coming days. If anyone who has already registered for the event wishes to request a refund, they can contact klowe@ Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
37 minutes ago
- Yahoo
Battle over SEPTA funding continues in Harrisburg: This Week in Pennsylvania
(WHTM) – The fight over funding SEPTA continues to brew in the State Capitol with the budget deadline looming. The transportation authority has thousands of stops across five southeastern counties. However, some lawmakers in Harrisburg say if funding keeps going toward SEPTA, there needs to be more funding for roads statewide where residents don't ride SEPTA. Scott Sauer, General Manager for SEPTA, joins This Week in Pennsylvania to discuss the ongoing structural deficit, SEPTA's biggest needs, and how SEPTA impacts all of Pennsylvania. Every week, This Week in Pennsylvania gives a comprehensive look at the week's biggest news events in Pennsylvania, provided by the abc27 News team, along with the latest updates on local stories. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Check your local listings for weekly air times. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Associated Press
an hour ago
- Associated Press
Kessler Topaz Meltzer & Check, LLP Reminds MicroStrategy Incorporated d/b/a Strategy Investors of Important Deadline in Securities Fraud Class Action Lawsuit
RADNOR, PA - June 8, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy ('Strategy') ( NASDAQ: MSTR ) on behalf of those who purchased or otherwise acquired Strategy securities between April 30, 2024, and April 4, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is July 15, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Strategy losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Strategy's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the anticipated profitability of Strategy's bitcoin-focused investment strategy and treasury operations was overstated; (2) the various risks associated with bitcoin's volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. THE LEAD PLAINTIFF PROCESS: Strategy investors may, no later than July 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Strategy investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
